Bipolar Disorders Treatment Market Research Report - Global Forecast till 2027

Bipolar Disorders Treatment Market Research Report: Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027

ID: MRFR/Pharma/1037-HCR | February 2021 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2019–2025 to 2020-2027. Cordially fill Sample form for updated data.

  Market Scenario The global bipolar disorders treatment market is expected to grow significantly over the forecast period. The global market was valued at USD 5600 million in 2018 and is projected to grow with 2.9% CAGR over the forecast period. Bipolar disorder is a manic-depressive disorder, which is a type of mental illness. It is characterized by mood swings and mood episodes appear during the illness. Manic and depressive episodes are common mood episodes observed in bipolar disorders. The government initiatives for treatment of bipolar disorders, advancement in combination drugs, and growing demand for antidepressant drugs are expected to drive the growth of the market. Moreover, growing research and development activities conducted by government and nonprofit organizations are contributing to the growth of the market. For instance, Harvard University started Harvard brain science initiative (HBI) for R&D on bipolar disorders. This program has provided USD 3 million in funds to the research and development related to bipolar disorders. The side effects associated with therapy, low diagnosis rate, and dearth of experts may hamper the growth of the global market during the assessment period.   Segmentation The global bipolar disorders and treatment market has been segmented on the basis of drug class, mechanism of action, and end user. Based on drug type, the global market has been classified into mood stabilizer, antipsychotic drugs, antianxiety drugs, antidepressant drugs, anticonvulsants, and others. Based on the mechanism of action, the global market has been segmented into selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitors, beta-blockers, tricyclic antidepressant drug, and others. The global market, by end user, has been segmented into hospitals and clinics, multispecialty centers, and others. The bipolar disorders treatment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bipolar disorders treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European bipolar disorders treatment market has been bifurcated into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The bipolar disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bipolar disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.   Key Players Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) are some of the key players operating in the global bipolar disorders treatment market.   Regional Market Summary   Global Bipolar Disorders Treatment Market Share (%), by Region, 2018 Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to dominate the global bipolar disorders and treatment market owing to technological advancement, presence of major players in the region, well-established healthcare system, and increasing cases of bipolar disorders in the region. According to the National Institute of Mental Health (NIMH), approximately 3% of adults in the US were suffering from bipolar disorders in 2016 and this percentage is expected to increase significantly in the future due to changing lifestyles.   The European market is expected to be the second-largest bipolar disorders and treatment market. The market growth in this region can be attributed to the increasing number of mental disorders, increasing government funding for treatment of bipolar disorders, and growing research and development activities related to mental health. For instance, in November 2017, Mental Health UK launched a partnership with Lloyds Banking Group to help bipolar disorder patients and to manage and improve their financial and mental health. Asia-Pacific is expected to be the fastest-growing bipolar disorders and treatment market during the forecast period owing to the increasing prevalence of genetic disorders, growing awareness about bipolar disorders, and rising investment by major players in the region. According to the Black Dog Institute, bipolar disorder is related with the genetic condition of an individual, if the parents are suffering from bipolar disorder it is more than 10% likely that their children will experience the same condition in future. The Middle East & Africa is expected to account for the smallest share of the bipolar disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. Global Bipolar Disorders Treatment Market, by Drug Type


  • Mood Stabilizer

  • Antipsychotic Drugs

  • Antianxiety Drugs

  • Antidepressant drugs

  • Anticonvulsants

  • Others


Global Bipolar Disorders Treatment Market, by Mechanism of Action

  • Selective Serotonin Reuptake Inhibitor

  • Serotonin Norepinephrine Reuptake Inhibitor

  • Monoamine Oxidase Inhibitors

  • Beta-Blockers

  • Tricyclic Antidepressant Drug

  • Others


Global Bipolar Disorders Treatment Market, by End User

  • Hospitals and Clinics

  • Multispecialty Centres

  • Others


Global Bipolar Disorders Treatment Market, by Region

  • Americas

    • North America

    • US

    • Canada

    • Latin America





  • Europe

    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Global Bipolar Disorders Treatment Market, by Key Players

  • Allergan

  • AstraZeneca

  • Eli Lilly and Company

  • GlaxoSmithKline

  • Abbott

  • Bristol-Myers Squibb

  • Johnson & Johnson

  • Pfizer Inc.

  • Cephalon Inc.

  • Otsuka America Pharmaceutical Inc.

  • Gedeon Richter plc

  • Others


Intended Audience

  • Bipolar disorders and treatment centers

  • Contract research organizations (CROs)

  • Research and development (R&D) companies

  • Government research laboratories

  • Independent research laboratories

  • Government and independent regulatory authorities

  • Market research and consulting service providers

  • Medical research laboratories

  • Academic medical institutes and universities



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 5600 Million
  • 2027: Significant Value
  •   CAGR   2.9% (2019–2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drug Type, Mechanism of Action and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary)
      Key Market Opportunities   side effects associated with therapy, low diagnosis rate, and dearth of experts
      Key Market Drivers

  • government initiatives for treatment of bipolar disorders
  • advancement in combination drugs
  • growing demand for antidepressant drugs


  • Frequently Asked Questions (FAQ) :


    bipolar disorders treatment market was valued at USD 5.6 billion in 2018.

    global market is expected to exhibit a strong 2.9% CAGR over the forecast period from 2019 to 2025.

    The growing prevalence of bipolar disorders is the major driver for the market.

    The Americas and Europe dominate the global bipolar disorder treatment market.

    Leading players in the market include Allergan, AstraZeneca, and Pfizer, among others.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Bipolar Disorders Treatment Market, by Drug Type

    6.1 Introduction

    6.2 Mood Stabilizer

    6.3 Anticonvulsant

    6.4 Antipsychotic Drug

    6.5 Antidepressant Drug

    6.6 Other

    Chapter 7. Global Bipolar Disorders Treatment Market, by Mechanism of Action

    7.1 Introduction

    7.2 Selective Serotonin Reuptake Inhibitor

    7.3 Serotonin Norepinephrine Reuptake Inhibitor

    7.4 Monoamine Oxidase Inhibitors

    7.5 Beta Blockers

    7.6 Tricyclic Antidepressant Drug

    7.7 Others

    Chapter 8. Global Bipolar Disorders and Treatment Market, by End User

    8.1 Introduction

    8.2 Hospitals and Clinics

    8.3 Multispecialty Centers

    8.4 Others

    Chapter 9. Global Bipolar Disorders Treatment Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 Latin America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Allergan

    11.1.1 Company Overview

    11.1.2 Drug Type Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Baxter International, Inc.

    11.2.1 Company Overview

    11.2.2 Drug Type Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 AstraZeneca

    11.3.1 Company Overview

    11.3.2 Drug Type Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Eli Lilly and Company

    11.4.1 Company Overview

    11.4.2 Technologys/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 GlaxoSmithKline

    11.5.1 Company Overview

    11.5.2 Drug Type Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Abbott

    11.6.1 Company Overview

    11.6.2 Drug Type Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Bristol-Myers Squibb

    11.7.1 Overview

    11.7.2 Drug Type Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Johnson & Johnson

    11.8.1 Overview

    11.8.2 Drug Type/ Technology Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Pfizer Inc.

    11.9.1 Overview

    11.9.2 Drug Type Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 Cephalon Inc.

    11.10.1 Overview

    11.10.2 Drug Type Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 Otsuka America Pharmaceutical Inc.

    11.11.1 Overview

    11.11.2 Drug Type Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Gedeon Richter plc

    11.12.1 Overview

    11.12.2 Drug Type Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Others

    Chapter 12. Appendix

    LIST OF TABLES

    Table 1 Global Bipolar Disorders Treatment Synopsis, 2020-2027

    Table 2 Global Bipolar Disorders Treatment Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Bipolar Disorders Treatment Market, by Region 2020-2027, (USD Million)

    Table 4 Global Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 5 Global Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 6 Global Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 7 North America: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 8 North America: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 9 North America: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 10 US: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 11 US: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 12 US: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 13 Canada: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 14 Canada: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 15 Canada: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 16 Latin America: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 17 Latin America: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 18 Latin America: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 19 Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 20 Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 21 Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 22 Western Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 23 Western Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 24 Western Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 25 Eastern Europe: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 26 Eastern Europe: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 27 Eastern Europe: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 28 Asia-Pacific: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 29 Asia-Pacific: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 30 Asia-Pacific: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    Table 31 Middle East & Africa: Bipolar Disorders Treatment Market, by Drug Type 2020-2027, (USD Million)

    Table 32 Middle East & Africa: Bipolar Disorders Treatment Market, by Mechanism of Action 2020-2027, (USD Million)

    Table 33 Middle East & Africa: Bipolar Disorders Treatment Market, by End User 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation of the Global Bipolar Disorders Treatment Market

    Figure 3 Segmentation Market Dynamics for the Global Bipolar Disorders Treatment Market

    Figure 4 Global Bipolar Disorders Treatment Market Share, by Drug Type, 2020

    Figure 5 Global Bipolar Disorders Treatment Market Share, by Mechanism of Action, 2020

    Figure 6 Global Bipolar Disorders Treatment Market Share, by End User, 2020

    Figure 7 Global Bipolar Disorders Treatment Market Share, by Region, 2020

    Figure 8 North America: Bipolar Disorders Treatment Market Share, by Country, 2020

    Figure 9 Europe: Bipolar Disorders Treatment Market Share, by Country, 2020

    Figure 10 Asia-Pacific: Bipolar Disorders Treatment Market Share, by Country, 2020

    Figure 11 Middle East & Africa: Bipolar Disorders Treatment Market Share, by Country, 2020

    Figure 12 Global Bipolar Disorders Treatment Market: Company Share Analysis, 2020 (%)

    Figure 13 Allergan: Key Financials

    Figure 14 Allergan: Segmental Revenue

    Figure 15 Allergan: Geographical Revenue

    Figure 16 Baxter International, Inc.: Key Financials

    Figure 17 Baxter International, Inc.: Segmental Revenue

    Figure 18 Baxter International, Inc.: Geographical Revenue

    Figure 19 AstraZeneca: Key Financials

    Figure 20 AstraZeneca.: Segmental Revenue

    Figure 21 AstraZeneca: Geographical Revenue

    Figure 22 Eli Lilly and Company.: Key Financials

    Figure 23 Eli Lilly and Company: Segmental Revenue

    Figure 24 Eli Lilly and Company: Geographical Revenue

    Figure 25 GlaxoSmithKline: Key Financials

    Figure 26 GlaxoSmithKline: Segmental Revenue

    Figure 27 GlaxoSmithKline: Geographical Revenue

    Figure 28 Abbott: Key Financials

    Figure 29 Abbott: Segmental Revenue

    Figure 30 Abbott: Geographical Revenue

    Figure 31 Bristol-Myers Squibb: Key Financials

    Figure 32 Bristol-Myers Squibb: Segmental Revenue

    Figure 33 Bristol-Myers Squibb: Geographical Revenue

    Figure 34 Johnson & Johnson: Key Financials

    Figure 35 Johnson & Johnson: Segmental Revenue

    Figure 36 Johnson & Johnson: Geographical Revenue

    Figure 37 Pfizer Inc.: Key Financials

    Figure 38 Pfizer Inc.: Segmental Revenue

    Figure 39 Pfizer Inc.: Geographical Revenue

    Figure 40 Cephalon Inc.: Key Financials

    Figure 41 Cephalon Inc.: Segmental Revenue

    Figure 42 Cephalon Inc.: Geographical Revenue

    Figure 43 Otsuka America Pharmaceutical Inc.: Key Financials

    Figure 44 Otsuka America Pharmaceutical Inc.: Segmental Revenue

    Figure 45 Otsuka America Pharmaceutical Inc.: Geographical Revenue

    Figure 46 Gedeon Richter plc: Key Financials

    Figure 47 Gedeon Richter plc: Segmental Revenue

    Figure 48 Gedeon Richter plc: Geographical Revenue